BeiGene has a total of three marketed proprietary products.

FAST NEWS: Beigene stock falls after Novartis terminates partnership

The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration.

Sales success comes with side effects for drug maker BeiGene

The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…

Daylight ahead for China’s battered semiconductor sector?

Interim results from Chinese semiconductor companies suggest change for the better lies ahead for this group     By Research-Select Major Chinese microchip maker Hua Hong Semiconductor Ltd. (1347.HK; 688347.SH) went…

CHINA BULLETIN: No Fun for European Firms in China

In this week’s issue European businesses get glum on China, consumers write off June 18 shopping fest and a three-week stock rally crashes. On a scale of 1 to 100, we give the week a 40 for offshore-listed China stocks.